C

CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765

Watchlist Manager
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Watchlist
Price: 27.08 CNY 1.04%
Market Cap: 72.4B CNY
Have any thoughts about
CSPC Innovation Pharmaceutical Co Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

427.9
Current
41.2
Median
13.5
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
427.9
=
Enterprise Value
70.2B CNY
/
EBITDA
164.1m CNY
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
CN
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Average EV/EBITDA: 456.4
427.9
119%
3.6
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
1 321.8
2-Years Forward
EV/EBITDA
64.8
3-Years Forward
EV/EBITDA
40.7

See Also

Discover More